About Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3
Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 is a rare disease catalogued by Orphanet (ORPHA:168566). It is associated with the TSFM gene. Search below for active recruiting clinical trials from ClinicalTrials.gov, or visit the Orphanet expert page for specialist centres, natural history studies, and patient registries.
Clinical Trial Eligibility Tips
What to know before applying to Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 trials.
Search ClinicalTrials.gov for "Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3" or filter by Orphanet code ORPHA:168566 to find disease-specific studies.
Ask your specialist to refer you to a Centre of Expertise — Orphanet lists all accredited centres for this condition worldwide.
Natural history studies and patient registries often enrol before drug trials open — contact the Orphanet patient community first.
Patient Resources
Find recruiting Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3. Updated daily.